NEW YORK (GenomeWeb News) — Sigma-Aldrich today said it has licensed from Epigentek technology for DNA modification, methylation quantitation, and protein/DNA interaction, which Sigma plans to use to develop its planned epigenetics research products.
 
The license is exclusive in the US and co-exclusive globally, Sigma-Aldrich said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.